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Chapter 1
Introduction to the thesis
A.M.G. Pasmooij, H.H. Pas and M.F. Jonkman
Center for Blistering Diseases, Department of Dermatology, 




The Center for Blistering Diseases in the Netherlands is located at the University 
Medical Center in Groningen. The referred patients can be divided in those with 
genetic blistering diseases, and those with acquired blistering diseases such as 
auto-immune diseases or adverse drug reactions. This thesis will focus on the first 
group of patients with the hereditary blistering disease epidermolysis bullosa (EB). 
Clinically, these patients are characterized by blistering and erosions of the skin and 
mucous membranes after trauma mostly starting at birth. From 1989 onwards more 
than 250 patients with EB from the Netherlands (and Belgium) were fully registered 
at the Department of Dermatology [1]. From each patient (family) history and clinical 
presentation were meticulously recorded, skin biopsies of intact and bullous skin 
were taken for immunofluorescence and electron microscopy, and DNA was isolated 
from peripheral blood cells on a routine basis. 
Research over the years has so far revealed 10 genes, all coding for proteins found 
in the epidermal basement membrane zone (BMZ), which underlie this skin disorder. 
The great number of mutations identified in these genes learned us more about the 
structure and function of the encoded proteins in the skin and other organs. Still, there 
are unusual phenotypes in EB that cannot be explained with the present knowledge. 
Therefore, this thesis will concentrate on these phenotypes and the accompanying 
underlying genotypes. Examples are patients with a clinically milder phenotype but 
with the same protein deficiency as those with more severe phenotypes, or with 
phenotypes that have never been observed before. Other interesting phenotypes 
are mosaic patients that have both affected and unaffected skin patches without 
any blistering tendency. Studying such remarkable phenotypes will teach us 
how the human body is able to cope with mutations, and how important specific 
regions of the affected molecules are for their adhesive function. From a diagnostic 
perspective, the identification of the disease-causing mutations by DNA analysis 
will give families with EB the chance to perform prenatal diagnostics. Moreover, 
studying the genetic reversion mechanisms underlying the unaffected skin patches 
in mosaic EB patients will possibly learn us how nature performs ‘natural gene 
therapy’. Understanding this phenomenon could bring ‘artificial’ correction of 
defective alleles closer to reality.
In the introduction to this thesis we will describe the protein complexes that are 
responsible for connecting the epidermal skin cells to the dermal matrix and those 
that interconnect the epidermal cells. Two adhesion proteins, both ‘EB’ molecules, 
which will become important in the forthcoming chapters, will be described in more 
detail. We will then introduce the present consensus classification system for EB 
that consists of three broad categories. Additionally, unusual EB phenotypes and 
therapy options will be discussed. Finally, at the end of this chapter, a short summary 
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is given of the aims of our studies and the questions that we would like to answer.
The Structure of Human Skin
The skin is the largest organ of the body, having a surface area of 1.8 m2 (≈8 x 
1010 cells) [2]. Its most important function is acting as a barrier to protect the body 
against water loss, mechanical and toxic insults, and invasion by disease-causing 
organisms and allergens. The skin is composed of two main tissues: the epidermis 
and the underlying connective tissue, consisting of the collagen-rich dermis and the 
fatty hypodermis or subcutis. The epidermis is an ectodermally derived continuously 
renewing stratified squamous epithelium composed largely of keratinocytes. 
In addition to the keratinocytes, it includes a small number of Langerhans cells, 
melanocytes and Merkel cells [3]. The five different layers: basal cell layer, stratum 
spinosum, stratum granulosum, stratum lucidum and stratum corneum, represent 
different stages of differentiation (fig. 1). The time period it takes a cell to originate at 
the inner-most basal cell layer until it is shed from the skin surface – a process called 
epidermal turnover - is in the order of a month [3]. The adnexal structures, including 
sweat glands, hair follicles and sebaceous glands, are despite their extension into the 
dermis of ectodermal origin. Adhesion between the cells in the epidermis is provided 
by desmosomes, intercellular junctions that provide specific attachment sites for 
the keratin intermediate filaments (KIF) present in the cytoplasm of keratinocytes 
[4]. These structures also participate in signal transduction and cell differentiation. 
Besides in epithelia, desmosomes are found in cardiomyocytes, meningeal cells 
and dendritic reticulum cells of lymphatic follicles. The hemidesmosomes, another 
cell junction, attach the basal keratinocytes of the epidermis to the extracellular 
matrix. Both these electron-dense structures, desmosomes and hemidesmosomes, 
maintain a strong network in order to provide sufficient tissue strength, but are 
also dynamic structures in order to permit continued cell renewal and maturation. 
Malfunctioning of KIF proteins or desmosomal proteins will perturb this network 
resulting in intraepidermal blistering diseases. Likewise, mutations in the proteins 
being part of the hemidesmosome complex lead to disturbance of dermal-epidermal 
adhesion and results in subepidermal blistering diseases.
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Figure 1 The five different layers of the epidermis are depicted on the left: stratum corneum, stratum 
lucidum, stratum granulosum, stratum spinosum and stratum basale. The basal cells are connected to 
the extracellular matrix of the dermis through hemidesmosomes (right part of the figure).
Stem Cells Responsible for Epidermal Renewal, Regeneration and 
Repair
To be able to renew, regenerate and repair the epidermis, stem cells are located 
in hair follicles, interfollicular epidermis, and sebaceous glands. These stem cells 
are cells capable of unlimited or prolonged self-renewal that can produce at least 
one type of highly differentiated descendant [5]. Besides these stem cells with high 
proliferative potential, a second type of proliferating keratinocyte is found in the 
epidermis that divides a small number of times before losing proliferative capacity 
and undergoing terminal differentiation. This keratinocyte is the transit-amplifying 
cell or progenitor cell [6]. “Transit”, because they are in transit from a stem-cell 
character to a differentiated character; “amplifying”, because the division cycles 
amplify the number of differentiated progeny that result from a single stem-cell 
division, thereby giving rise to the suprabasal layers [7]. Taylor et al [8] showed that 
these transit-amplifying cells could migrate horizontally along the epidermal BMZ. 
Finally, the differentiated cells are shed from the skin surface as squames.
The percentage of stem cells in the epidermis is approximately 10% [9,10]. Their 
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distribution is in groups of 9-14 cells in diameter within the basal epidermal layer 
and above the dermal papillae (the site where the dermis comes closest to the 
skin surface) [10]. Populational asymmetry is achieved by the fact that a stem cell 
divides asymmetrically and gives rise to daughter cells that can be stem cell or 
transit-amplifying cell [10]. Responses to variable physiological needs, as when 
increased production of epidermal cells is required after injury, are facilitated by this 
populational asymmetry. The slowly dividing cells capable of regenerating the hair 
follicle and provisionally the adjacent interfollicular epidermis reside in the ‘bulge’ 
of the outer root sheath of the hair follicle [8]. The proteins p64, CD34, integrin α6, 
integrin	β1, keratin 15, keratin 19, S100A4 and S100A6 are all highly expressed in 
epithelial stem cells [10-13]. Unfortunately, these surface markers are not specific 
enough to serve as marker proteins. A unique stem cell marker that would enable in 
vivo and in vitro targeting is currently still missing. 
Hemidesmosome Important for Basal Cell Attachment
Besides mediating the adhesion of epithelial cells to the underlying BMZ, 
hemidesmosomes also transduce signals for cell spreading, cell proliferation and 
basement membrane organization [14]. Hemidesmosomes are found in basal 
cells of stratified- and pseudostratified epithelia, complex epithelia, as well as in 
myoepithelial cells of glandular epithelia. Ultrastructurally, they appear as electron-
dense condensations of less than 50 nm thickness that reside at intervals near 
the plasma membrane of basal epithelial cells [15]. Hemidesmosomes can be 
divided into three distinctive regions: (a) the inner plaque connected to the KIF 
composed of keratin 5 and keratin 14; (b) the outer plaque of approximately 20-40 
nm, located on the cytoplasmic side of the plasma membrane; (c) the sub-basal 
dense plate, thin electron dense structures situated extracellularly beneath the 
outer plaque immediately below the plasma membrane in the basement membrane 
[15,16] (fig. 2). The basement membrane allows free diffusion of proteins and other 
macromolecules across the membrane.
Next page:
Figure 2 The hemidesmosome-stable adhesion complex. The chain of adhesion molecules that con-
nects the epidermis to the dermis is depicted in dark grey. Deficiency of one of the dark grey-colored 





Six hemidesmosomal proteins have so far been identified and characterized: 
integrin	α6, integrin β4 [17], plectin [18], type XVII collagen [19] (also known as 
bullous pemphigoid antigen 2 or BP180), BP230 (also known as bullous pemphigoid 
antigen 1) [20,21], and tetraspanin/CD151 [22]. While the inner plaque contains 
BP230 and plectin, the outer plaque consists of integrin α6β4, type XVII collagen 
and tetraspanin/CD151 [22,23]. In the areas beneath the hemidesmosomes the 
lamina lucida is traversed by thin thread-like structures called anchoring filaments. 
The anchoring filaments, mainly composed of laminin-332 (LM-332, formerly named 
laminin-5), extend from the plasma membrane in the hemidesmosome through the 
sub-basal dense plates into the lamina densa [24]. Other proteins that form part of 
these filaments are laminin-311, laminin-511 and the extracellular part of type XVII 
collagen [25,26]. The lamina densa, the continuous electron-dense layer where the 
anchoring filaments attach to, consists mainly of type IV collagen. Nidogen and 
perlecan are other glycoproteins of the lamina densa [27]. The anchoring fibrils, 
predominantly composed of type VII collagen, extend from the lamina densa into 
the papillary dermis where they loop back into the lamina densa or insert into 
anchoring plaques [28]. The hemidesmosomal plaques and plate, the anchoring 
filaments, together with the anchoring fibrils form the hemidesmosome-stable 
adhesion complex [29].
Two types of hemidesmosomes are recognized in the skin. Type II hemidesmosomes 
consist of integrin α6β4, tetraspanin/CD151 and plectin only, whereas type I 
hemidesmosomes additionally contain type XVII collagen and BP230 [22].
Since in this thesis the focus will mostly be on two molecules, type XVII collagen 
and LM-332, both highly important in the chain of adhesion molecules, these will be 
discussed beneath in more detail.
Type XVII collagen
Type XVII collagen, also known as the 180-kDa bullous pemphigoid antigen, is 
a glycosylated transmembrane protein of 1,497 amino acid residues [30-32]. It 
has a type II orientation, meaning that the amino-terminal region is cytoplasmic, 
whereas the carboxy-terminal domain spans the lamina lucida (fig. 2) [19,31]. This 
extracellular tail, comprising approximately two thirds of the protein, contains 15 
interrupted collagenous domains (Gly-X-Y motif), designated “COL1” to “COL15” 
[32]. The length of these regions varies from 15 to 242 amino acids, with COL15 by 
far the largest collagenous domain [33]. Like all collagens, three chains (type XVII 
collagen α1) can form a triple helix configuration. Triple helix formation is supposed 
to proceed from N- to C-terminus [34]. Involvement of the membrane proximal 
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16th noncollagenous A (NC16A) domain (residues 490-566) in the formation of the 
stable polypeptide has been suggested by Areida et al [34]. The final shape of the 
resulting homotrimeric molecule is a globular head with a central rod and a flexible 
tail [33,35,36]. Moreover, immunoelectron microscopy indicated that this flexible tail 
forms at least one loop structure in the lamina densa [36]. The type XVII collagen 
ectodomain, a 120-kDa soluble trimer, is suggested to be proteolytically shed from 
the cell surface within the NC16A domain by zinc-dependent metalloproteinases 
belonging to the ADAMs (a disintegrin and metalloproteinase) family [37,38]. This 
molecule is known as the linear IgA disease antigen 1 (LAD-1) [39-41]. Subsequently, 
LAD-1 can be cleaved to a second soluble form of 97-kDa, representing the linear 
IgA bullous disease antigen of 97 kDa (LABD97) [42,43]. The full length polypeptide 
consists of codons 1-1497, the 120-kDa soluble LAD-1 of residues 524-1497 and 
LABD97 of 531-1209 [43,44]. Different hypotheses exist about the specific role 
of these soluble ectodomains. LAD-1 and LABD97 can either be waste products 
without specific function that result from cleavage of the full length protein [45]. 
It has also been suggested that they play a role in strengthening the epidermal-
dermal adhesion or keratinocyte migration [37]. Although type XVII collagen almost 
certainly has signal-transduction properties [46] and is involved in cell migration 
[47], its main function is to act as a transmembrane link in the molecular chains 
that anchor the cytoskeleton of the basal keratinocytes to the basement membrane 
[25,36]. Molecular interactions with BP230 (aa 145-230), plectin (aa 145-230), and 
the intracellular tail of the integrin β4 subunit, by the first 230 N-terminally located 
amino acids and a second binding-site more C-terminally located (aa 231-401) were 
observed for the cytoplasmic domain [48,49]. The extracellular tail also mediates 
binding, to integrin α6 (aa 506-519) [50,51] as well as to LM-332; this binding region 
located in the region encompassing residues 1175-1497 [47]. Type XVII collagen 
is crucial for maintaining adhesion between the epidermis and dermis because it 
was found to be mutated in patients with the recessively inherited genetic blistering 
disease generalized atrophic benign EB (GABEB), a subset of non-Herlitz junctional 
EB [MIM 226650] [52,53]. In addition, type XVII collagen can lead to autoimmunity. It 
is an autoantigen in the autoimmune bullous disorders bullous pemphigoid, herpes 
gestationis, lichen planus pemphigoides, and various forms of mucous membrane 
pemphigoid [54]. How type XVII collagen becomes an autoimmune target is 
completely unknown but it is food for thought that almost all autoantigens in skin 
diseases are adhesion molecules.
The	COL17A1 gene, encoding type XVII collagen, comprises 56 exons that range in 
size from 27 to 390 bp, and together lead to a coding sequence of 4,491 nucleotides 
[30,55]. The gene spans 52 kb of the genome on the long arm of chromosome, in 
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band 10q24.3. The untranslated and coding sequence is highly conserved between 
mouse and man, showing an 86% overlap [32,33]. Differential splicing of exon 56 
results in two alternative transcripts that differ 610 nucleotides in length in the 3’ 
untranslated region (UTR) [56]. At the 5’ end six different 5’UTRs are found of which 
two are major [57].
Laminin-332
The LM-332 protein (epiligrin, kalinin, nicein, BM600 or laminin 5 [58]), synthesized 
by the basal cells, is the major adhesion ligand in the connection of the epithelial 
cells to the underlying BMZ by binding to hemidesmosomal components like integrin 
α6β4 [24] and anchoring fibrils via type VII collagen [59,60]. By interacting with 
integrins	α3β1 [24,61] and α6β4 [62], LM-332 influences also the cell’s behavior, as 
in cell migration by normal and malignant epithelial cells [63]. In invading epithelial 
cells the protein is highly overexpressed [64]. Laminins are composed of different 
combinations of α, β and γ subunits. Currently, 16 laminin trimers are known from 
different α (5), β (3), and γ (3) chains [58,65]. Like the name suggests, LM-332 
consists of three subunit polypeptides, the α3, β3, and γ2 chains, encoded by the 
distinct genes, LAMA3, LAMB3, and LAMC2 respectively [66-70]. These chains 
assemble into a cross-like structure with one coiled-coil long arm and three short 
arms, representing the N-terminal regions of each chain. After secretion into the 
extracellular matrix this heterotrimer precursor undergoes proteolytic processing to 
a smaller form [24,68]. The 200-kDa α3 chain is first cleaved to 165 kDa and finally 
to 145 kDa, the 155-kDa γ2 chain is processed to 105 kDa, whereas the 140-kDa β3 
chain remains unprocessed. LAMB3, encoding this latter β3 chain, contains 23 exons 
giving rise to a cDNA of 3,516 bp encoding 1,172 amino acids [71]. LAMA3, LAMB3	
and LAMC2 map to chromosomes 18q11.2, 1q32 and 1q25-1q31, respectively. 
Mutations in these three genes were found in patients with junctional EB suggesting 
that all three chains are crucial for structural integrity [72-75]. The clinical outcome 
of the disease depends on the mutation type, i.e. nonsense mutations on both 
alleles in one of the genes encoding LM-332 (LAMA3, LAMB3, LAMC2) result in 
the Herlitz type [MIM 226700], first described by Herlitz in 1935, which is frequently 
lethal during the first two years of life [72,75,76], whereas a combination of a non-
sense mutation together with a missense mutation or splice-site mutation result in 
the less severe non-Herlitz (non-lethal) type [MIM 226650] with a normal lifespan, 




Mutations in the genes encoding proteins involved in the described hemidesmosome-
stable adhesion complex result in EB. The prevalence between countries varies from 
19 in 1 million in the USA to 49 in 1 million in Scotland [79,80]. In the Netherlands 
the prevalence is approximately 45 in 1 million, leading to a population of about 725 
patients with EB in the Netherlands and yearly 20 newborns with this disease [1]. 
The expected carrier frequency is approximately 1:100 [81]. Molecular cloning and 
development of mutation detection strategies led to the identification of mutations in 
as many as 10 different genes that underlie different forms of EB. The main feature of 
this heterogeneous group of autosomally inherited skin disorders is fragility of the skin 
and mucous membranes after mild mechanical trauma resulting in blister formation 
starting mostly at birth. EB produces a broad spectrum of clinical manifestations, 
its severity varying from a relatively mild to a severe condition. The mild forms 
appear with blisters on friction-exposed skin areas (e.g. EB simplex), whereas the 
more severe forms show widespread epidermolysis and chronic ulcerations with 
mutilating scarring (e.g. recessive dystrophic EB). In rare cases other tissues can 
be involved, e.g. EB with muscular dystrophy and cardiomyopathy [MIM 226670]. 
The enormous phenotypic variability is explained by the level of expression of the 
mutated genes, the types and combinations of mutations, their positions on the 
genes, and their consequences at the mRNA and protein levels.
Classification of Epidermolysis Bullosa
In 1989 the first consensus meeting on the diagnosis and classification of inherited 
EB was held. The classification system, published in 1991, that resulted from this 
meeting was a clinico-pathological categorization [82]. Based on the level of tissue 
separation within the cutaneous BMZ by diagnostic immuno epitope mapping and/
or transmission electron microscopy, three major categories were distinguished: 
EB simplex (EBS), junctional EB (JEB) and dystrophic EB (DEB); (1) in EBS tissue 
separation occurs through the subnuclear region of the basal keratinocytes; (2) in 
JEB the blister formation takes place below the plasma membrane within the lamina 
lucida of the BMZ; and (3) in DEB tissue separation occurs below the lamina densa 
in the papillary dermis (fig. 3). EBS and DEB are most abundant in the Dutch EB 
patient population, with percentages of 40% and 35%, respectively [1]. The other 
25% can be classified as having JEB. Depending on the specific population these 
percentages can differ; JEB cases comprise 2-5% of all EB cases in the USA, but 
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this value is much higher in the Middle Eastern populations: 27% of the cases 
[80,83]. It was proposed that this high proportion of recessive EB subtypes may be 
due to the high inbreeding coefficient characteristic of populations of the Middle 
East.
Figure 3 Level of blister formation in different categories of EB. In EBS the plane of cleavage is through 
the basal cells, whereas in JEB blister formation is seen at the level of the lamina lucida. Separation in 
DEB takes place beneath the lamina densa, in the dermis.
Further subclassification is based upon the genetic mode of transmission and 
clinical phenotype, leading to more than 30 different clinical variants. For example, 
the clinical spectrum of the most common form in the Netherlands, EBS, ranges 
from mild blistering of the hands and feet (EBS Weber-Cockayne [MIM 131800]; 
EBS with mottled pigmentation [MIM 131960]) to more generalized blistering (EBS 
Koebner [MIM 131900]; EBS Dowling-Meara [MIM 131760]). The description of all 
these clinical variants is beyond this chapter.
About ten years later in May 1999 this classification system was discussed and 
revised [84]. This revised classification system (table 1) aimed to categorize EB 
in a simple and clear manner, so that it could be readily learned and adopted by 
practicing physicians and medical geneticists, as well as by researchers specializing 
in genetic skin diseases. 
As can be seen in table 1, depending on the type and location of mutations, different 
mutations in the same gene may result in completely different phenotypes. For 
instance, mutations in the type VII collagen gene (COL7A1) can result in dominant 
DEB or recessive DEB, the latter characterized by a complete absence (recessive 
DEB-Hallopeau-Siemens [MIM 226600]) or reduction (leading to milder clinical 
forms) of anchoring fibrils in the patient’s skin. It can also be that mutations result 
in a phenotype that has never been observed before. In chapter 7 we will describe 
a child born with such a new phenotype. The newborn had epidermolysis that 
progressed from 30% to 70% within the first day and to 90% by the fifth day. Due 
to extensive transcutaneous fluid loss the boy died ten days postpartum. Our aim 
was to identify the disease-causing mutations underlying this severe phenotype.
Chapter 1
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Table 1 Revised classification of inherited EB, based on clinical phenotype and genotype, for the most 
commonly observed and well-characterized variants or subtypes of this disease [84]
Major EB type Minor EB subtype Protein/gene systems involved





JEB-nH Laminin-332; type XVII collagen
JEB-PA† Integrin α6β4 
DEB (“dermolytic EB”) DDEB Type VII collagen
RDEB-HS Type VII collagen
RDEB-nHS Type VII collagen
DDEB, Dominant dystrophic EB; EBS-DM, EBS, Dowling-Meara; EBS-K, EBS, Koebner; EBS-MD, EBS 
with muscular dystrophy; EBS-WC, EBS, Weber-Cockayne; JEB-H, JEB, Herlitz; JEB-nH, JEB, non-Her-
litz; JEB-PA, JEB with pyloric atresia; RDEB-HS, recessive dystrophic EB, Hallopeau-Siemens; RDEB-
nHS, RDEB, non-Hallopeau-Siemens.
†Some cases of EB associated with pyloric atresia may have intraepidermal cleavage or both intra-
lamina lucida and intraepidermal clefts.
Unexpected Phenotypes in Patients with COL17A1 Mutations 
In patients with EB due to COL17A1 mutations interesting phenotypes have been 
observed. This paragraph divides these phenotypes into two sections. Section 1 
describes EB patients with revertant mosaicism. In this phenomenon a mechanism 
takes place that reverts the mutant phenotype to the wild-type phenotype, i.e. 
healthy skin without blistering tendency. It may also be that the reversion results in 
re-expression of deficient protein, but without clinical improvement. As this reversion 
is only partial, this type of mosaicism is referred to as ‘partial revertant mosaicism’. 
Like mentioned before, the common phenotype in patients with COL17A1 mutations 
is GABEB. In section 2 we will describe less common phenotypes as milder ones 
and phenotypes with features of EBS [85].
1 Revertant mosaicism
In 1997 Jonkman and colleagues described the first mosaic EB patient [86] 
(summarized in table 2). The patient, with COL17A1 mutations, displayed a mosaic 
pattern in her skin with patches of clinically affected and unaffected skin. In contrast 
to the affected skin the unaffected skin had reverted to the wild-type phenotype and 
showed no blister formation after rubbing. This reversion was caused by a gene 
conversion of the maternal mutation 1706delA-bearing allele. In another patient 
with mosaic type XVII collagen expression the reversion process was caused by a 
compensatory second-site mutation [87]. To detect this additional mutation in the 
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DNA the authors made use of laser capture microdissection, so that they could 
separately isolate the population of cells that stained positively and negatively 
for type XVII collagen [87]. The 2-bp insertion, 4080insGG, corrected the frame-
shift caused by the inherited 2-bp deletion, 4003delTC, and led to expression of a 
stable type XVII collagen molecule with a 25 amino-acid exchange. In contrast to 
the first patient, the revertant skin still blistered, although type XVII collagen protein 
was produced. Therefore, this patient is an example of a partial revertant. In a later 
study, protein structural analysis on the double mutant (4003delTC-4080insGG) 
and 4003delTC mutant showed that the changes hardly affected the structure 
and stability of the extracellular domain [88]. Therefore, Fu et al [88] suggested the 
presence of a ligand binding site in the NC4 domain. 
Two groups reported patients with reversions in the KRT14 gene, encoding keratin 
14 [89,90]. For the EBS case described by Smith et al [90] it was suggested that 
silencing of the dominant-negative allele by a secondary nonsense mutation led to 
the amelioration of the phenotype during life. In all these above mentioned cases 
reversion mechanisms at the DNA level where underlying the revertant mosaicism. 
Nevertheless, it is also possible that this regulation takes place at the RNA level. 
Schuilenga-Hut et al [89] described a patient with a mosaic pattern in her skin, but 
without skin improvement. No additional DNA changes were observed, whereas 
analysis of mRNA isolated from mosaic skin keratinocytes revealed an additional 
in-frame transcript (1844T→G, 1845Δ6) that codes for an abnormal keratin 14 
polypeptide with a two residue deletion and one amino acid change. Therefore 
‘RNA editing’ was held responsible for the restoration of the reading frame of the 
RNA transcript. RNA editing comprises mechanisms that can alter nucleotides in 
the RNA after it has been transcribed from DNA, but before it is translated into 
protein (for reviews [91,92]).
In chapter 2, we will describe two mosaic patients. We reinvestigated the original 
patient described in 1997 and a second patient with EB due to COL17A1 mutations 
who had a patch of clinically healthy skin on his right middle finger. The reversion 
mechanisms present in the revertant skin biopsies were directly investigated using 
laser dissection microscopy. Chapter 3 will also deal with revertant mosaicism. In 
this chapter two unrelated patients with GABEB caused by mutations in the LAMB3	
gene were studied. One proband had unaffected skin on his right shoulder, whereas 
the other patient developed clinically healthy skin on his left lower leg during life. In 
both chapters the genetic mechanisms underlying these corrections - in the past 










































































































































































2 Milder phenotypes 
Depending on the gene in which the mutations are located a broad variety exists 
in EB phenotypes. For instance, LM-332 is a more essential protein than type 
XVII collagen in retaining the dermo-epidermal connection. Complete absence of 
LM-332 results in death within two years after birth, while absence of type XVII 
collagen does not severely affect the lifespan. At least that is what is generally 
believed. Recently, however, Abu Sa’d et al [83] published a report about a child 
homozygous for a small deletion, 4144del4, in the COL17A1 gene, who died soon 
after birth. The authors state that it could be ruled out that the death was caused by 
poor care conditions, because the child was hospitalized. In this light, it is perhaps 
interesting to note that an Iraqi family also lost two children, whom were most likely 
homozygous for the 823delA mutation (Prof D. Murrell, unpublished results). It is not 
known whether the quality of health care facilities played a role in the early death of 
the infants in this Iraqi family. Despite these cases with a lethal outcome, normally, 
mutations in COL17A1 lead to the GABEB phenotype without affecting the lifespan. 
The clinical symptoms of continuous blistering start at birth after minor friction. 
Other characteristics are atrophic hypopigmented skin, dystrophic nails and dental 
anomalies. Also the hair pattern is affected, with alopecia seen in a typical pattern 
on the scalp, partial absence of eyelashes and eyebrows and absence of pubic and 
axillary hair [93]. The disease does not affect the growth, and lacks anemia, scarring 
and milia. In a few cases focal palmoplantar callosities have been reported [94,95]. 
Ultrastructurally, rudimentary hemidesmosomes and abnormal association with 
the KIF is observed [96]. Nowadays 61 COL17A1 mutations are reported, mainly 
consisting of nonsense mutations and insertions or deletions leading to premature 
termination codons (PTCs), reduction of the COL17A1 mRNA transcripts due to 
nonsense-mediated mRNA decay [97] and to the GABEB phenotype (fig. 4 and 
table 3). In contrast, missense mutations are rarer.
Another factor that influences the clinical outcome is the mutation type. For instance, 
it can be that a splice-site mutation still generates some in-frame transcripts resulting 
in some partly functional protein and therefore a milder phenotype. Huber et al [85] 
described a patient with a phenotype with predominant features of EBS. The proband 
was compound heterozygous for a large deletion in the intracellular domain of type 
XVII collagen extending from intron 2 to intron 15 (158del1172; I18del389) and a 
nonsense mutation in exon 51 (R1226X). Unexpectedly, intraepidermal cleavage 
was observed due to the deletion of the cytoplasmic domain, fitting with a diagnosis 
of EBS, whereas in patients with two COL17A1 null mutations a split through the 
lamina lucida is observed. Another mild phenotype, found in six Italian families, due 
to the in-frame deletion of a part of the protein was reported by Ruzzi et al [98]. 
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Blistering was strictly limited to trauma sites and oral mucosal lesions were rare 
[99]. The unusually mild phenotype was also deducible from the lack of alopecia in 
two individuals. The nonsense mutation R795X in exon 33 caused skipping of the 
mutation-bearing exon, leading to a slightly smaller type XVII collagen protein. Since 
this PTC-induced outsplicing occurred in all patients and it is also described in other 
genes, one might think of a general mechanism [98]. The occurrence of a missense 
mutation may also result in a mild localized phenotype, with predominantly acral 
blistering and normal hair, as observed in a patient homozygous for the R1303Q 
mutation [100]. Moreover, a patient with mild mucosal and lack of hair involvement 
was reported by Guerriero et al [101]. Alopecia was completely absent and secondary 
hair was normal in this man. These data above demonstrate that mutations can 
result in unexpected phenotypes, depending on the function of the affected domain. 
Seemingly, the degree of skin, mucous membranes and hair involvement can vary 
considerably between patients with type XVII collagen deficiency.
Another mutation type that may influence the clinical outcome is a missense 
mutation acting in a dominant-negative fashion. In principle, mutations in COL17A1	
are recessive. However, several missense mutations in the fifteenth collagenous 
region are described that have a dominant-negative effect giving rise to dental 
anomalies. McGrath et al [102] reported the first case of a glycine substitution, 
G627V, which inherits in a dominant fashion. The offspring of the described EB 
patient was carrier of this missense mutation in the fifteenth collagenous region 
and showed dental anomalies with random pitted dental enamel hypoplasia, but 
no skin fragility. To identify whether alterations in the assembly or stability of the 
type XVII collagen collagenous region where responsible for the dominant-negative 
effect, Olague-Marchan et al [103] decided to perform structural analysis on 
recombinant wild-type and G627V mutants. Their conclusion was that the random 
pitted dental enamel hypoplasia was the result of a local destabilization of the triple 
helix structure. Moreover, structural analysis of recombinant type XVII collagen with 
glycine substitutions was also studied by Tasanen et al [104] and Väisänen et al 
[105]. Besides G627V, the other mutations that caused isolated dental anomalies 
were G609D, G612R and G633D. The outcome was the same as previously 
described for G627V; all substitutions markedly influenced the stability. Although 
no clear genotype-phenotype correlation is observed for COL17A1 mutations [106], 
the phenotypes associated with mutations in the fifteenth collagenous domain 
were milder, with acral or generalized mild/moderate blistering of the skin, than the 
GABEB-phenotype observed in patients with COL17A1 null mutations [105].
In this thesis we describe three patients with COL17A1 mutations who have also 
a milder manifestation of clinical symptoms with localized blistering confined to 
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hands, lower legs and face. In chapters 4 and 5 we ask ourselves the question why 
the clinical phenotypes were milder than in ‘classical’ GABEB patients, even though 
both patients had mutations on both COL17A1 alleles. In addition to these patients, 
we describe another patient with an extremely mild phenotype in chapter 6. We 
named this less severe phenotype ‘localized atrophic benign EB’ (LABEB). This 
chapter also reveals five new deletions in the population of Dutch patients, setting 
the total number of COL17A1 mutations on 66 (fig. 4).
Figure 4 Schematic representation of the type XVII collagen protein. The protein consists of three do-
mains, an intracellular domain of 466 residues (green), a transmembrane domain of 23 amino acids (red) 
and an extracellular tail of 1008 residues with fifteen interrupted collagenous domains (blue) and sixteen 
noncollagenous domains (yellow). The COL17A1 gene encoding this protein, depicted above, contains 
56 exons. All COL17A1 mutations found so far are indicated. The mutations in red are COL17A1 muta-
tions that were identified in patients with EB in the Netherlands. The references of each mutation can be 
found in table 3. This figure can be found on page 186 in the appendix Color figures.
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Table 3 All COL17A1 mutations reported up to March 12, 2006 with location and effect on RNA
Mutation Location Consequence References
M1T exon 2 MIS* [133]
R9X exon 2 PTC [133]
I18del389 (158del1172) exon 2-exon 15 In-frame skip [85]
209-210insCA exon 5 PTC [134]
W65X exon 4 PTC [135]
367insT exon 5 PTC [135]
520delAG exon 7 PTC [136]
R145X (538C→T) exon 8 PTC [100,104]
569-2A→G
(or 464-2A→Ga)
intron 8 Acceptor splice site [135]
823delA exon 10 PTC D. Murrell, 
Australia
G258X (877G→T) exon 11 PTC [137]
884delC exon 11 PTC [133]
S265C (899C→G) exon 11 MIS [138]
1284delA exon 15 PTC this	thesis
1365delC exon 16 PTC this	thesis
1372+1G→T intron 16 Donor splice site [135]
1706delA exon 18 PTC [76,86]
G539E (1721G→Aa) exon 18 MIS [136]
R565X exon 19 PTC [135]
1877-2A→C intron 21 Acceptor splice site [139]
G609D (1826G→Aa) exon 22 MIS [105]
G612R (1834G→Aa) exon 22 MIS [105]
G627V (1985G→T) exon 23 MIS [102]
G633D (2003G→A) exon 23 MIS [104]
2342delG exon 30 PTC [140]
Q751X (2356C→T) exon 30 (PTC) In-frame skip [141]
2441-2A→G (or 2336-
2A→G	a)
intron 31 Acceptor splice site [105,142]
2441-1G→T intron 31 Acceptor splice site [143]
2468-2A→G
(or 2363-2A→Ga)
intron 32 Acceptor splice site [135]
R795X (2488C→T) exon 33 (PTC) In-frame skip [98,99]
G803X (2512 G→T) exon 34 PTC [144]
2518del10 exon 34 PTC [96]
2666delTT exon 37 PTC [136]
L855X (2669T→G) exon 37 PTC [145]
2690insT exon 37 PTC [135]
2881delA exon 41 PTC [146]
2944del5 exon 43 PTC [55]
2965delG exon 43 PTC [136]
3002-2A→C
(or 2897-2A→Ca)
intron 43 Acceptor splice site [135]
3053-1G→C
(or 2948-1G→Ca)
intron 44 Acceptor splice site [135,147]
Q1016X (3151C→T) exon 45 PTC [100]
Q1023X (3172T→C) exon 45 PTC [55]
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V1026M exon 46 MIS [148]
Q1058X exon 46 PTC [133]
3236delC exon 46 PTC this	thesis
3432delT exon 48 PTC [139,141]
3513delC
(or 3408delC	a)
exon 48 PTC [135]
3514ins25 exon 48 PTC [102]
3600-3601delCT exon 49 PTC this	thesis
R1169X exon 49 PTC [135]
3674insT exon 50 PTC [148]
R1226X (3781C→T) exon 51 PTC [53,76,85,86,100,
105,136,149]
3782G→C exon 51 correcting R1226X [149]
3871+1G→C intron 51 Donor splice site [147,150]
3871+1G→A
(or 3766+1 G→Aa)
intron 51 Donor splice site [135]
3801insC exon 51 PTC [135]
3827insC exon 51 PTC [135]
4003delTC exon 52 PTC [87,144,151] 
R1303Q (4013G→A) exon 52 MIS [100]
4080insGG exon 52 correcting 4003delTC [87]
4144del4 exon 52 PTC [83]
4150insG exon 52 PTC [53]
4261+1G→C intron 52 Donor splice site [152]
Q1403X (4312C→T) exon 53 PTC [144]
4335delC exon 53 PTC [95]
4410_4413dupCATT exon 54 PTC [153]
4424-5insC exon 54 PTC [149]
4425delT exon 54 PTC this	thesis
4463-1G→A intron 54 correcting 4424-5insC [149]
*MIS, missense mutation. a	There is no consensus about the numbering of nucleotides in COL17A1. 
Two different approaches exist; one by Giudice et al [33] including 105 nucleotides until the start codon 
is reached, and another approach starting with the number 1 at the site of the start codon. Both ap-
proaches are used, sometimes even in the same article. For example, in the article of Varki et al [135] 
for the splice-site mutation 1372+1G→T the first 105 nucleotides are included, whereas for the other 
reported splice-site mutations this is not the case (464-2A→G; 2363-2A→G; 2897-2A→C; 2948-1G→C	
and 3766+1G→A). In this table we used Giudice’s approach [33].
Therapy
Until now no curative treatment is available for EB patients, although research on 
gene therapy is very active [107-115]. Research is especially focused on the severe 
forms of EB, i.e. the junctional form of EB caused by deficiency of LM-332 and on 
DEB. The two basic approaches to therapeutic gene delivery to the skin involve 
ex vivo and in vivo gene delivery. In vivo gene delivery is more simple and direct 
than	ex vivo delivery, which involves culturing cells from a skin biopsy, selecting 
transgenic cells and returning the grown epithelial sheet to the donor. Despite 
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these disadvantages, ex vivo gene delivery has been the major focus, especially 
because successfulness of gene transfer and the unwanted presence of replication 
competent viruses can be easily checked. Besides, grafting of skin equivalent 
cultures has already been successful in RDEB patients [116]. Different methods 
have been used in the ex vivo transfer	of	COL7A1 cDNA into DEB keratinocytes 
including a lentivirus- [108] and a retrovirus approach [111]. The concerns on 
problems observed with the use of viruses in therapy of blood and liver disease, 
started the search for virus-free approaches, including transfer of naked DNA [110] 
and the phi C31 bacteriophage integrase-based approach [109]. In the naked DNA-
approach plasmid DNA encoding the gene is intradermally injected, transported 
through the BMZ into the epidermis, taken up into the cytoplasm and then into the 
nucleus by the epidermal keratinocytes and finally transcribed into mRNA [110]. 
In all the above mentioned studies, correction led to expression of recombinant 
collagen VII into a tight linear BMZ component, and synthesis of anchor fibrils. 
Like said before, a drawback using corrected keratinocytes is that large numbers 
of cells should be grown to cover the body surface followed by skin grafting with 
the possibility of postoperative scarring. Another possible approach is correction of 
fibroblasts, since both keratinocytes and fibroblasts synthesize type VII collagen, 
although fibroblasts to a lesser extent [117]. Culturing fibroblasts is also easier than 
culturing keratinocytes. The cells can be passaged 20 to 30 times in vitro [118]. 
Different groups investigated the possibilities of therapeutic intradermal injection 
of fibroblasts [112,119]. Ortiz-Urda et al [112] succeeded in transducing COL7A1	
using a phi C31 integrase-based non-viral approach, whereas Woodley et al [119] 
made use of a lentiviral vector to restore type VII collagen. Recently, Goto et al 
[115] showed that gene-transferred fibroblasts can supply even more collagen VII 
to the BMZ than gene-transferred keratinocytes [115]. Hence, fibroblasts seem to 
have a preference above keratinocytes for correction in DEB. Even more, Woodley 
et al [120] also investigated protein-based therapy for RDEB. One injection of 
recombinant type VII collagen in mice resulted in stable incorporation in the BMZ 
lasting for at least 3 months, showing as well that collagens have a slow turnover 
times and are long-lived molecules [120,121]. Human or bovine collagen injected 
into human skin to correct photoageing can last for 4 to 6 months.
For JEB different approaches have also been undertaken. Type XVII collagen-
deficient, integrin β4-deficient, and LM-332-deficient JEB cells have been corrected 
in vitro [107,122-124]. Retroviruses were used in successful transduction of JEB 
stem cells in vitro [107,122,123]. Because of the concerns about retroviruses, Ortiz-
Urda et al [113] made use of the Sleeping Beauty synthetic transposable element to 
integrate	the	LAMB3 cDNA into the genome of JEB keratinocytes. They could show 
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for the first time stable gene delivery by transposon-mediated gene transfer, resulting 
in LM-322 protein expression, hemidesmosome formation and lack of blistering. 
Especially the stability of this correction is important as this is one of the major 
issues to address for in vivo application. A recent reported study with great potential 
was performed by Mavilio et al [125]. In this Phase-I-clinical trial the patient’s own 
genetically corrected epidermal stem cells were used to grow epidermal sheets. 
These grafts were transplanted on both legs of a 30-yr-old male patient affected 
by non-lethal JEB due to LAMB3 mutations. The transplanted skin remained stable 
in the absence of blistering or inflammation for the duration of the follow-up, i.e. 4 
months at the time of writing [125]. Instead of using gene addition, our group tried to 
correct a DNA point mutation using chimeric RNA/DNA oligonucleotides (RDOs) in 
immortalized keratinoyctes of two patients with EB who had homozygous mutations 
in	KRT14 and COL17A1, respectively [126]. Although successful usage of the RDO 
technology has been reported, persistent failure of gene repair in the keratinocytes 
occurred. Therefore, the authors were in favor of an international collaboration to 
prove (or disapprove) its applicability. In addition, Dallinger et al [127] investigated 
another strategy, the possibility of using spliceosome-mediated RNA trans-splicing, 
since at that time the viral vectors had a size limitation for insertions. Aimed for was 
the correction of the 4003delTC mutation in the large COL17A1 gene. Replacement 
was shown by co-transfection of constructs into keratinocytes in a β-gal activity 
assay. The transfection efficiency was rather low, thus it remains to be seen if this 
approach would be applicable to an in vivo situation. 
Other methods that can be considered are gene inhibition approaches that act at 
the level of mRNA inhibition via recognition of mutated sequences, such as the 
delivery of antisense oligonucleotides [128] and ribozymes [129]. A limitation of 
such strategies is that the choice of the target region on the mRNA is dictated by 
the location of the mutations. 
Another therapy that should be considered in EB treatment is the use of aminoglyco-
side antibiotics. Recently several articles were published on use of aminoglycosides 
in human to treat genetic diseases [130-132]. Aminoglycosides can suppress 
nonsense-mediated decay, a quality-control system that detects and degrades 
RNA transcripts containing nonsense mutations, thereby permitting translational 
“read-through”, resulting in expression of a full-length protein in patients who have 
stop mutations. Since approximately one third of genetic defects are caused by 
nonsense mutations, this approach could be applicable to a broad range of genetic 
diseases [130]. In a study in patients with cystic fibrosis caused by PTCs in the CFTR	
gene the first results were positive. Gentamicin nose drops led to expression of full-
length CFTR protein, and correction of the typical electrophysiological abnormalities 
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caused by CFTR dysfunction [130]. An advantage of these antibiotics is that they 
can be topically applied. A drawback, however, is that they act not specifically on 
the mutated gene, but on all nonsense-mediated decay processes present in the 
cell. Also, unwanted side effects like hearing-loss and renal insufficiency are known 
of gentamicin use. Therefore a new drug, PTC124, was manufactured with only 
rare and mild side effects. At the moment PTC124 is tested in patients with cystic 
fibrosis and patients with Duchenne muscular dystrophy are being recruited [131]. 
Altogether, it will be interesting to see the outcome of these studies, probably mid 
2006, and to investigate if such antibiotic therapy is also useful in EB caused by 
nonsense mutations, e.g. in patients with the frequent LAMB3 nonsense mutation 
R635X. Until now, only one initial indicative study has been performed in a Hailey-
Hailey patient [132].
Aim of the Thesis
All together, this thesis focuses on the genotyping of unusual phenotypes in EB in 
order to obtain a better understanding of this genetic disease. In chapters 2 and 3	
we will investigate four patients with revertant mosaicism with clinically healthy skin 
area and affected skin area. More specifically, the genetic mechanisms underlying 
these reversion processes of COL17A1 and LAMB3 are studied. Accompanying 
questions that will be addressed are: When did these reversion events occur? Did 
these revertant patches of healthy skin expand over the years? Is there a preference 
for a specific reversion mechanism? Is there ‘a driving force’, such as UV-light?
Besides, in our polyclinic we saw patients with COL17A1 mutations that had resulted 
in a milder localized blistering phenotype than the GABEB-phenotype. Chapters 4, 
5 and 6 describe why despite the mutations in COL17A1 these patients had such 
a mild phenotype. Chapter 7 is dedicated to a new phenotype with acantholysis 
of the suprabasal cells of the epidermis. Finally, our results and the implications of 
our findings in the search for an EB treatment are discussed in chapter 8 as well as 





Jonkman MF, Rulo HFC, Duipmans JC (2003). Van gen naar ziekte; epidermolysis bullosa door 
mutaties in eiwitten in of rond het hemidesmosoom. Ned Tijdschr Geneeskd 147:1108-1113
Claudinot S, Nicolas M, Oshima H, Rochat A, Barrandon Y (2005) Long-term renewal of hair 
follicles from clonogenic multipotent stem cells. Proc Natl Acad Sci U S A 102:14677-14682
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) Molecular biology of the cell, 






























Garrod D, Chidgey M, North A (1996) Desmosomes: differentiation, development, dynamics 
and disease. Curr Opin Cell Biol 8:670-678
Watt FM, Hogan BLM (2000) Out of Eden: Stem cells and their niches. Science 287:1427-
1430
Watt FM (2002) Role of integrins in regulating epidermal adhesion, growth and differentiation. 
EMBO J 21:3919-3926
Fuchs E, Raghavan S (2002) Getting under the skin of epidermal morphogenesis. Nature Rev 
Genet 3:199-209
Taylor G, Lehrer MS, Jensen PJ, Sun T-T, Lavker RM (2000) Involvement of follicular stem cells 
in forming not only the follicle but also the epidermis. Cell 102:451-461
Potten CS, Morris RJ (1988) Epithelial stem cells in vivo. J Cell Sci 10:45-62
Jones PH, Harper S, Watt FM (1995) Stem cell patterning and fate in human epidermis. Cell 
80:83-93
Lane EB, Wilson CA, Hughes BR, Leigh IM (1991) Stem cells in hair follicles: cytoskeletal
studies. Ann NY Acad Sci 642:197-213
Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al (2004) Defining the epithe-
lial stem cell niche in skin. Science 303:359-363
Ito M, Liu Y, Yang Z, Nguyen J, Liang F, Morris RJ, et al (2005) Stem cells in the hair follicle bulge 
contribute to wound repair but not to homeostasis of the epidermis. Nat Med 11:1351-1354
Borradori L, Sonnenberg A (1996) Hemidesmosomes: roles in adhesion, signalling and human 
diseases. Curr Opin Cell Biol 8:647-656
Borradori L, Sonnenberg A (1999) Structure and function of hemidesmosomes: more than sim-
ple adhesion complexes. J Invest Dermatol 112:411-418
Garrod DR (1993) Desmosomes and hemidesmosomes. Curr Opin Cell Biol 5:30-40
Stepp MA, Spurr-Michaud S, Tisdale A, Elwell J, Gipson IK (1990) Alpha 6 beta 4 integrin 
heterodimer is a component of hemidesmosomes. Proc Natl Acad Sci USA 87:8970-8974
Hieda Y, Nishizawa Y, Uematsu J, Owaribe K (1992) Identification of a new hemidesmosomal 
protein, HD1: a major, high molecular mass component of isolated hemidesmosomes. J Cell 
Biol 116:1497-1506
Hopkinson SB, Ridelle KS, Jones JCR (1992) Cytoplasmic domain of the 180-kD bullous pem-
phigoid antigen, a hemidesmosomal component: Molecular and cell biologic characterization. 
J Invest Dermatol 99:264-270
Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI (1981) Characterization of bul-
lous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithe-
lia. Cell 3:897-903
Guo L, Degenstein L, Dowling J, Yu QC, Wollmann R, Perman B, et al (1995) Gene targeting 
of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and
neurologic degeneration. Cell 81:233-243
Sterk LM, Geuijen CA, Oomen LC, Calafat J, Janssen H, Sonnenberg A (2000) The tetraspan 
molecule CD151, a novel constituent of hemidesmosomes, associates with the integrin α6β4 
and may regulate the spatial organization of hemidesmosomes. J Cell Biol 149:969-982
Nievers MG, Schaapveld RQ, Sonnenberg A (1999) Biology and function of hemidesmosomes. 
J Cell Sci 111:1659-1672
Carter WG, Ryan MC, Gahr PJ (1991) Epiligrin, a new cell adhesion ligand for integrin alpha 3 
beta 1 in epithelial basement membranes. Cell 65:599-610
Masunaga T, Shimizu H, Yee C, Borradori L, Lazarova Z, Nishikawa T, et al (1997) The extracel-
lular domain of BPAG2 localizes to anchoring filaments and its carboxyl terminus extends to 
the lamina densa of normal human epidermal basement membrane. J Invest Dermatol 109:200-
206
Aumailley M, Rousselle P (1999) Laminins of the dermo-epidermal junction. Matrix Biol 18:19-
28
Aumailley M, Krieg T (1996) Laminins: a family of diverse multifunctional molecules of basement 
membranes. J Invest Dermatol 106:209-214
Keene DR, Sakai LY, Lunstrum GP, Morris NP, Burgeson RE (1987) Type VII collagen forms an 
extended network of anchoring fibrils. J Cell Biol 104:611-621
Burgeson RE, Christiano AM (1997) The dermal-epidermal junction. Curr Opin Cell Biol 9:651-
658






















tion of collagenous domains and chromosomal assignment of human 180-kDa bullous pem-
phigoid antigen-2, a novel collagen of stratified squamous epithelium. J Biol Chem 266:24064–
24069
Giudice GJ, Squiquera HL, Elias PM, Diaz L (1991) Identification of two collagen domains within 
the bullous pemphigoid autoantigen, BP180. J Clin Invest 87:734-738
Li K, Tamai K, Tan EM, Uitto J (1993) Cloning of type XVII collagen: complementary and genomic 
DNA sequences of mouse 180-kilodalton bullous pemphigoid antigen (BPAG2) predict an inter-
rupted collagenous domain, a transmembrane segment, and unusual features in the 5’-end of 
the gene and the 3’-untranslated region of the mRNA. J Biol Chem 268:8825–8834
Giudice GJ, Emery DJ, Diaz LA (1992) Cloning and primary structural analysis of the bullous 
pemphigoid autoantigen BP180. J Invest Dermatol 99:243-250
Areida SK, Reinhardt DP, Muller PK, Fietzek PP, Kowitz J, Marinkovich MP, et al (2001) Proper-
ties of the collagen type XVII ectodomain. Evidence for n- to c-terminal triple helix folding. J 
Biol Chem 276:1594-1601
Hirako Y, Usukura J, Nishizawa Y, Owaribe K (1996) Demonstration of the molecular shape 
of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation. J Biol 
Chem 271:13739-13745
Nonaka S, Ishiko A, Masunaga T (2000) The extracellular domain of BPAG2 has a loop structure 
in the carboxy terminal flexible tail in vivo. J Invest Dermatol 115:889-892
Franzke CW, Tasanen K, Schacke H, Zhou Z, Tryggvason K, Mauch C, et al (2002) Transmem-
brane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. 
EMBO J 21:5026-5035
Franzke CW, Tasanen K, Borradori L, Huotari V, Bruckner-Tuderman L (2004) Shedding of colla-
gen XVII/BP180: structural motifs influence cleavage from cell surface. J Biol Chem 279:24521-
24529
Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ (1996) LAD-1, the linear IgA 
bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by 
epidermal cells. J Invest Dermatol 106:734-738
Pas HH, Kloosterhuis GJ, Heeres K, van der Meer JB, Jonkman MF (1997) Bullous pemphigoid 
and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycopro-
tein with antigenic cross-reactivity to BP180. J Invest Dermatol 108:423-429
Pas HH, Kloosterhuis GJ, Nijenhuis M, de Jong MC, van der Meer JB, Jonkman MF (1999) Type 
XVII collagen (BP180) and LAD-1 are present as separate trimeric complexes. J Invest Dermatol 
112:58-61
Zone JJ, Taylor TB, Kadunce DP, Meyer LJ (1990) Identification of the cutaneous basement 
membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermato-
sis. J Clin Invest 85:812-820
Zone JJ, Taylor TB, Meyer LJ, Petersen MJ (1998) The 97 kDa linear IgA bullous disease antigen 
is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, 
BPAg2. J Invest Dermatol 110:207-210
Hirako Y, Nishizawa Y, Sitaru C, Opitz A, Marcus K, Meyer HE, et al (2003) The 97-kDa (LABD97) 
and 120-kDa (LAD-1) fragments of bullous pemphigoid antigen 180/type XVII collagen have dif-
ferent N-termini. J Invest Dermatol 121:1554-1556
Hirako Y, Yoshino K, Zillikens D, Owaribe K (2003) Extracellular cleavage of bullous pemphigoid 
antigen 180/type XVII collagen and its involvement in hemidesmosomal disassembly. J Bio-
chem (Tokyo) 133:197-206
Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP, et al (2000) Autoanti-
bodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 
from cultured human keratinocytes. J Invest Dermatol 115:842-848
Tasanen K, Tunggal L, Chometon G, Bruckner-Tuderman L, Aumailley M (2004) Keratinocytes 
from patients lacking collagen XVII display a migratory phenotype. Am J Pathol 164:2027-
2038
Hopkinson SB, Jones JC (2000) The N-terminus of the transmembrane protein BP180 interacts 
with the N-terminal domain of BP230, thereby mediating keratin cytoskeleton anchorage to the 
cell surface at the site of the hemidesmosome. Mol Biol Cell 11:277-286
Koster J, Geerts D, Favre B, Borradori L, Sonnenberg A (2003) Analysis of the interactions 
between BP180, BP230, plectin and the integrin alpha6beta4 important for hemidesmosome 

























Hopkinson SB, Baker SE, Jones JC (1995) Molecular genetic studies of a human epidermal 
autoantigen (the 180-kD bullous pemphigoid antigen/BP180): identification of functionally im-
portant sequences within the BP180 molecule and evidence for an interaction between BP180 
and alpha 6 integrin. J Cell Biol 130:117-125
Hopkinson SB, Findlay K, deHart GW, Jones JC (1998) Interaction of BP180 (type XVII col-
lagen) and alpha6 integrin is necessary for stabilization of hemidesmosome structure. J Invest 
Dermatol 111:1015-1022
Jonkman MF, de Jong MCJM, Heeres K, Pas HH, van der Meer JB, Owaribe K, et al (1995) 
180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epider-
molysis bullosa. J Clin Invest 95:1345–1352
McGrath JA, Gatalica B, Christiano AM, Owaribe K, Mc-Millan JR, Eady RAJ, et al (1995) Mu-
tations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmem-
brane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet 
11:83–86
van den Bergh F, Giudice GJ (2003) BP180 (type XVII collagen) and its role in cutaneous biology 
and disease. Adv Dermatol 19:37-71
Gatalica B, Pulkkinen L, Li K, Kuokkanen K, Ryynanen M, McGrath JA, et al (1997) Cloning of 
the human type XVII collagen gene (COL17A1), and detection of novel mutations in generalized 
atrophic benign epidermolysis bullosa. Am J Hum Genet 60:352–365
Molnar K, van der Steege G, Jonkman MF, Nijenhuis M, Husz S, van der Meer JB, et al (2000) 
Two type XVII collagen (BP180) mRNA transcripts in human keratinocytes: a long and a short 
form. Clin Exp Dermatol 25:71-76
van Zalen S, Nijenhuis N, Jonkman MF, Pas HH (2006) Two major 5’ untranslated regions for 
COL17A1 mRNA. submitted
Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, et al (2005) 
A simplified laminin nomenclature. Matrix Biol 24:326-332
Rousselle P, Keene DR, Ruggiero F, Champliaud MF, Rest M, Burgeson RE (1997) Laminin 5 
binds the NC-1 domain of type VII collagen. J Cell Biol 138:719-728
Chen M, Marinkovich MP, Jones JC, O’Toole EA, Li YY, Woodley DT (1999) NC1 domain of type 
VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-
like repeats. J Invest Dermatol 112:177-183
Rousselle P, Aumailley M (1994) Kalinin is more efficient than laminin in promoting adhesion of 
primary keratinocytes and some other epithelial cells and has a different requirement for integrin 
receptors. J Cell Biol 125:205-214
Niessen CM, Hogervorst F, Jaspars LH, de Melker AA, Delwel GO, Hulsman EH, et al (1994) The 
alpha 6 beta 4 integrin is a receptor for both laminin and kalinin. Exp Cell Res 211:360-367
Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S, et al (1999) 
Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer 
Res 59:5596-5601
Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, et al (1994) The gamma 2 chain of 
kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am 
J Pathol 145:782-791
Miner JH, Yurchenco PD (2004) Laminin functions in tissue morphogenesis. Annu Rev Cell Dev 
Biol 20:255-284
Rousselle P, Lunstrum GP, Keene DR, Burgeson RE (1991) Kalinin: an epithelium-specific base-
ment membrane adhesion molecule that is a component of anchoring filaments. J Cell Biol 
114:567-576
Kallunki P, Sainio K, Eddy R, Byers M, Kallunki T, Sariola H, et al (1992) A truncated laminin 
chain homologous to the B2 chain: structure, spatial expression, and chromosomal assign-
ment. J Cell Biol 119:679-693
Marinkovich MP, Lunstrum GP, Burgeson RE (1992) The anchoring filament protein kalinin is 
synthesized and secreted as a high molecular weight precursor J Biol Chem 267:17900-17906
Ryan MC, Tizard R, VanDevanter DR, Carter WG (1994) Cloning of the LamA3 gene encoding 
the alpha 3 chain of the adhesive ligand epiligrin. Expression in wound repair. J Biol Chem 269: 
22779-22787
Gerecke DR, Wagman DW, Champliaud MF, Burgeson RE (1994) The complete primary struc-
ture for a novel laminin chain, the laminin B1k chain. J Biol Chem 269:11073-11080






















of the beta 3 chain gene (LAMB3) of human laminin 5, a candidate gene in junctional epidermo-
lysis bullosa. Genomics 25:192-198
Aberdam D, Galliano MF, Vailly J, Pulkkinen L, Bonifas J, Christiano AM, et al (1994) Herlitz’s 
junctional epidermolysis bullosa is linked to mutations in the gene (LAMC2) for the gamma 2 
subunit of nicein/kalinin (LAMININ-5). Nature Genet 6:299-304
Pulkkinen L, Christiano AM, Airenne T, Haakana H, Trygvason K, Uitto J (1994) Mutations in the 
gamma-2 chain gene (LAMC2) of kalinin/laminin 5 in the junctional forms of epidermolysis bul-
losa. Nature Genet 6:293-298
Kivirikko S, McGrath JA, Baudoin C, Aberdam D, Ciatti S, Dunnill MG, et al (1995) A homozygous 
nonsense mutation in the alpha 3 chain gene of laminin 5 (LAMA3) in lethal (Herlitz) junctional 
epidermolysis bullosa. Hum Mol Genet 4:959-962
Kivirikko S, McGrath JA, Pulkkinen L, Uitto J, Christiano AM (1996) Mutational hotspots in the 
LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa. Hum Mol Genet 
5:231-237
Jonkman MF, de Jong MCJM, Heeres K, Steijlen P, Owaribe K, Kuster W, et al (1996) Genera-
lized atrophic benign epidermolysis bullosa: either 180-kd bullous pemphigoid antigen or la-
minin-5 deficiency. Arch Dermatol 132:145–150
McGrath JA, Ashton GH, Mellerio JE, Salas-Alanis JC, Swensson O, McMillan JR, et al (1999) 
Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa 
through in-frame skipping of exons containing non-sense or frameshift mutations. J Invest Der-
matol 113:314-321
Nakano A, Chao SC, Pulkkinen L, Murrell D, Bruckner-Tuderman L, Pfendner E, et al (2002) 
Laminin 5 mutations in junctional epidermolysis bullosa: molecular basis of Herlitz vs. non-Her-
litz phenotypes. Hum Genet 110:41-51
McKenna KE, Walsh MY, Bingham EA (1992) Epidermolysis bullosa in Northern Ireland. Br J 
Dermatol 127:318-321
Fine JD, Bauer EA, McGuire J, Moshell A (1999) Epidermolysis bullosa: clinical, epidemiological 
and laboratory advances and the findings of the National Epidermolysis Bullosa Registry. Balti-
more, MD: The John Hopkins University Press
Nakano A, Lestringant GG, Paperna T, Bergman R, Gershoni R, Frossard P, et al (2002) Junc-
tional epidermolysis bullosa in the Middle East: clinical and genetic studies in a series of con-
sanguineous families. J Am Acad Dermatol 46:510-516
Fine JD, Bauer EA, Briggaman RA, Carter DM, Eady RA, Esterly NB, et al (1991) Revised clini-
cal and laboratory criteria for subtypes of inherited epidermolysis bullosa. A consensus report 
by the Subcommittee on Diagnosis and Classification of the National Epidermolysis Bullosa 
Registry. J Am Acad Dermatol 24:119-135
Abu Sa’d J, Indelman M, Pfendner E, Falik-Zaccai TC, Mizrachi-Koren M, Shalev S, et al (2006) 
Molecular epidemiology of hereditary epidermolysis bullosa in a Middle Eastern population. J 
Invest Dermatol 126:777-781
Fine JD, Eady RAJ, Bauer EA, Briggaman RA, Bruckner-Tuderman L, Christiano A, et al (2000) 
Revised classification system for inherited epidermolysis bullosa: Report of the second interna-
tional consensus meeting on diagnosis and classification of epidermolysis bullosa. J Am Acad 
Dermatol 42:1051-1066
Huber M, Floeth M, Borradori L, Schäcke H, Rugg EL, Lane EB, et al (2002) Deletion of the 
cytoplasmatic domain of BP180/collagen XVII causes a phenotype with predominant features 
of epidermolysis bullosa simplex. J Invest Dermatol 118:185-192
Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, et al (1997) Revertant mosa-
icism in epidermolysis bullosa caused by mitotic gene conversion. Cell 88:543–551
Darling TN, Yee C, Bauer JW, Hintner H, Yancey KB (1999) Revertant mosaicism: partial correc-
tion of a germ-line mutation in COL17A1 by a frame-restoring mutation. J Clin Invest 103:1371–
1377
Fu CL, Giudice GJ, Van den Bergh F (2006) Protein structural analysis of BP180 mutant iso-
forms linked to non-Herlitz junctional epidermolysis bullosa. J Invest Dermatol 126:232-234
Schuilenga-Hut PH, Scheffer H, Pas HH, Nijenhuis M, Buys CH, Jonkman MF (2002) Partial 
revertant mosaicism of keratin 14 in a patient with recessive epidermolysis bullosa simplex. J 
Invest Dermatol 118:626-630
Smith FJ, Morley SM, McLean WH (2004) Novel mechanism of revertant mosaicism in Dowling-
























Maas S, Rich A (2000) Changing genetic information through RNA editing. Bioessays 22:790-
802
Davidson NO (2002) The challenge of target sequence specificity in C-->U RNA editing. J Clin 
Invest 109:291-294
Hintner H and Wolff K (1982) Generalized atrophic benign epidermolysis bullosa. Arch Dermatol 
118:375-384
Paller AS, Fine JD, Kaplan S, Pearson RW (1986) The generalized atrophic benign form of junc-
tional epidermolysis bullosa. Experience with four patients in the United States. Arch Dermatol 
122:704-710
Mitsui H, Watanabe T, Komine M, Nakamura H, Shimizu H, Tamaki K (2005) Focal palmoplantar 
callosities in non-Herlitz junctional epidermolysis bullosa. J Am Acad Dermatol 52:371-373
McMillan JR, McGrath JA, Tidman MJ, Eady RA (1998) Hemidesmosomes show abnormal as-
sociation with the keratin filament network in junctional forms of epidermolysis bullosa. J Invest 
Dermatol 110:132-137
van Zalen S, Pasmooij AMG, Nijenhuis AM, Jonkman MF, Pas HH (2006) Effect of nonsense 
mutations on COL17A1 mRNA transcript levels in keratinocytes of junctional epidermolysis 
bullosa patients. submitted
Ruzzi L, Pas H, Posteraro P, Mazzanti C, Didona B, Owaribe K, et al (2001) A homozygous non-
sense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA 
accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. J Invest 
Dermatol 116:182-187
Mazzanti C, Gobello T, Posteraro P, Paradisi M, Meneguzzi G, Chinni L, et al (1998) 180-kDa 
bullous pemphigoid antigen defective generalized atrophic benign epidermolysis bullosa: report 
of four cases with an unusually mild phenotype. Br J Dermatol 138:859-866
Schumann H, Hammami-Hauasli N, Pulkkinen L, Mauviel A, Kuster W, Luthi U, et al (1997) Three 
novel homozygous point mutations and a new polymorphism in the COL17A1 gene: relation 
to biological and clinical phenotypes of junctional epidermolysis bullosa. Am J Hum Genet 
60:1344-1353
Guerriero C, De Simone C, Venier A, Rotoli M, Posteraro P, Zambruno G, et al (2001) Non-Herlitz 
junctional epidermolysis bullosa without hair involvement associated with BP180 deficiency. 
Dermatology 202:58-62
McGrath JA, Gatalica B, Li K, Dunnill MG, McMillan JR, Christiano AM, et al (1996) Compound 
heterozygosity for a dominant glycine substitution and a recessive internal duplication mutation 
in the type XVII collagen gene results in junctional epidermolysis bullosa and abnormal denti-
tion. Am J Pathol 148:1787-1796
Olague-Marchan M, Twining SS, Hacker MK, McGrath JA, Diaz LA, Giudice GJ (2000) A
disease-associated glycine substitution in BP180 (type XVII collagen) leads to a local destabili-
zation of the major collagen triple helix. Matrix Biol 19:223-233
Tasanen K, Floeth M, Schumann H, Bruckner-Tuderman L (2000) Hemizygosity for a glycine 
substitution in collagen XVII: unfolding and degradation of the ectodomain. J Invest Dermatol 
115:207-212
Väisänen L, Has C, Franzke C, Hurskainen T, Tuomi ML, Bruckner-Tuderman L, et al (2005) 
Molecular mechanisms of junctional epidermolysis bullosa: Col 15 domain mutations decrease 
the thermal stability of collagen XVII. J Invest Dermatol 125:1112-1118
Bauer JW, Lanschuetzer C (2003) Type XVII collagen gene mutations in junctional epidermolysis 
bullosa and prospects for gene therapy. Clin Exp Dermatol 28:53-60
Robbins PB, Lin Q, Goodnough JB, Tian H, Chen X, Khavari PA (2001) In vivo	restoration	of	
laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad 
Sci U S A 98: 5193-5198
Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, et al (2002) Restoration of type 
VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32:670-
675
Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, et al (2002) Stable nonviral 
genetic correction of inherited human skin disease. Nat Med 8:1166-1170
Sawamura D, Akiyama M, Shimizu H (2002) Direct injection of naked DNA and cytokine trans-
gene expression: implications for keratinocyte gene therapy. Clin Exp Dermatol 27:480-484
Baldeschi C, Gache Y, Rattenholl A, Bouille P, Danos O, Ortonne JP, et al (2003)  Genetic cor-



























Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA (2003) Injection of ge-
netically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. 
J Clin Invest 111:251-255
Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA (2003) Sustainable correction of 
junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther 
10:1099-1104
Jiang QJ, Uitto J (2005) Animal models of epidermolysis bullosa--targets for gene therapy. J 
Invest Dermatol 124: xi-xiii
Goto M, Sawamura D, Ito K, Abe M, Nishie W, Sakai K, et al (2006) Fibroblasts show more po-
tential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis 
bullosa. J Invest Dermatol 126:766-772
Falabella AF, Valencia IC, Eaglstein WH, Schachner LA (2000) Tissue-engineered skin (Apligraf) 
in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 136:1225-1230
Ryynanen J, Sollberg S, Parente MG, Chung LC, Christiano AM, Uitto J (1992) Type VII collagen 
gene expression by cultured human cells and in fetal skin. Abundant mRNA and protein levels 
in epidermal keratinocytes. J Clin Invest 89:163-168
Krueger GG (2000) Fibroblasts and dermal gene therapy: a minireview. Hum Gene Ther 11:2289-
2296
Woodley DT, Krueger GG, Jorgensen CM, Fairley JA, Atha T, Huang Y, et al (2003) Normal and 
gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII col-
lagen at the basement membrane zone. J Invest Dermatol 121:1021-1028
Woodley DT, Keene DR, Atha T, Huang Y, Lipman K, Li W, et al (2004) Injection of recombinant 
human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat 
Med 10:693-695
Burgeson (1993) Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J Invest Der-
matol 101:252-255
Dellambra E, Prislei S, Salvati AL, Madeddu ML, Golisano O, Siviero E, et al (2001) Gene correc-
tion of integrin beta4-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes 
establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly. J Biol Chem 
276:41336-41342
Gagnoux-Palacios L, Vailly J, Durand-Clement M, Wagner E, Ortonne JP, Meneguzzi G (1996) 
Functional re-expression of laminin-5 in laminin-gamma2-deficient human keratinocytes modi-
fies cell morphology, motility, and adhesion. J Biol Chem 271:18437-18444 
Seitz CS, Giudice GJ, Balding SD, Marinkovich MP, Khavari PA (1999) BP180 gene delivery in 
junctional epidermolysis bullosa. Gene Ther 6:42-47
Mavilio F, Ferrari S, Di Nunzio F, Maruggi G, Bonini C, Capurro S, et al (2006) Correction of 
laminin-5 deficient junctional epidermolysis bullosa by transplantation of genetically modified 
epidermal stem cells. A Phase-I clinical trial, abstract, AAD 2006 
van der Steege G, Schuilenga-Hut PH, Buys CH, Scheffer H, Pas HH, Jonkman MF (2001) Per-
sistent failures in gene repair. Nat Biotechnol 19:305-306
Dallinger G, Puttaraju M, Mitchell LG, Yancey KB, Yee C, Klausegger A, et al (2003) Develop-
ment of spliceosome-mediated RNA trans-splicing (SMaRT) for the correction of inherited skin 
diseases. Exp Dermatol 12:37-46
Wraight CJ, White PJ (2001) Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 
90:89-104
Lewin AS, Glazer PM, Milstone LM (2005) Gene therapy for autosomal dominant disorders of 
keratin. J Investig Dermatol Symp Proc 10:47-61
Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, et al (2003) Gentamin-induced 
correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J 
Med 349:1433-1441
Ainsworth C (2005) Running the red light. Nature 438:726-728
Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM (2006) Aminoglycosides as 
potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J Invest Dermatol 
126: 229-231
Pfendner EG, Nakano A, Pulkkinen L, Christiano AM, Uitto J (2003) Prenatal diagnosis for epi-
dermolysis bullosa: a study of 144 consecutive pregnancies at risk. Prenat Diagn 23:447-456





















tion in three patients with generalized atrophic benign epidermolysis bullosa from a Japanese 
family: molecular genetic and immunohistochemical studies. J Hum Genet 50:483-489
Varki R, Sadowski S, Pfendner E, Uitto J (2006) Epidermolysis bullosa. I. Molecular genetics of 
the junctional and hemidesmosomal variants. J Med Genet (ahead of print)
Floeth M, Fiedorowicz J, Schacke H, Hammami-Hausli N, Owaribe K, Trueb RM, et al (1998) 
Novel homozygous and compound heterozygous COL17A1 mutations associated with
junctional epidermolysis bullosa. J Invest Dermatol 111:528-533
Shimizu H, Takizawa Y, Pulkkinen L, Zone JJ, Matsumoto K, Saida T, et al (1998) The 97 kDa 
linear IgA bullous dermatosis antigen is not expressed in a patient with generalized atrophic 
benign epidermolysis bullosa with a novel homozygous G258X mutation in COL17A1. J Invest 
Dermatol 111:887-892
Wu Y, Li G, Zhu X (2002) A novel homozygous point mutation in the COL17A1	gene	in	a	Chinese	
family with generalized atrophic benign epidermolysis bullosa. J Dermatol Sci 28:181-186
Pasmooij AMG, van der Steege G, Pas HH, Smitt JH, Nijenhuis AM, Zuiderveen J, et al (2004) 
Features of epidermolysis bullosa simplex due to mutations in the ectodomain of type XVII col-
lagen. Br J Dermatol 151:669-674
Scheffer H, Stulp RP, Verlind E, van der Meulen M, Bruckner-Tuderman L, Gedde-Dahl T Jr, et 
al (1997) Implications of intragenic marker homozygosity and haplotype sharing in a rare auto-
somal recessive disorder: the example of the collagen type XVII (COL17A1) locus in generalised 
atrophic benign epidermolysis bullosa. Hum Genet 100:230-235
Pasmooij AMG, van Zalen S, Nijenhuis AM, Kloosterhuis AJ, Zuiderveen J, Jonkman MF, et al 
(2004) A very mild form of non-Herlitz junctional epidermolysis bullosa: BP180 rescue by out-
splicing of mutated exon 30 coding for the COL15 domain. Exp Dermatol 13:125-128
Chavanas S, Gache Y, Tadini G, Pulkkinen L, Uitto J, Ortonne JP, et al (1997) A homozygous in-
frame deletion in the collagenous domain of bullous pemphigoid antigen BP180 (Type XVII col-
lagen) causes generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 109:74-78
Darling TN, Yee C, Koh B, McGrath JA, Bauer JW, Uitto J, et al (1998) Cycloheximide facilitates 
the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1	
in a patient with generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 110:165-
169
Darling TN, McGrath JA, Yee C, Gatalica B, Hametner R, Bauer JW, et al (1997) Premature 
termination codons are present on both alleles of the bullous pemphigoid antigen 2/type XVII 
collagen gene in five Austrian families with generalized atrophic benign epidermolysis bullosa. 
J Invest Dermatol 108:463-468
Floeth M, Bruckner-Tuderman L (1999) Digenic junctional epidermolysis bullosa: mutations in 
COL17A1 and LAMB3 genes. Am J Hum Genet 65:1530-1537
Mellerio JE, Denyer JE, Atherton DJ, Eady RA, McGrath JA (1998) Prognostic implications of 
determining 180 kDa bullous pemphigoid antigen (BPAG2) gene/protein pathology in neonatal 
junctional epidermolysis bullosa. Br J Dermatol 138:661-666
Pulkkinen L, Marinkovich MP, Tran HT, Lin L, Herron GS, Uitto J (1999) Compound heterozygo-
sity for novel splice site mutations in the BPAG2/COL17A1 gene underlies generalized atrophic 
benign epidermolysis bullosa. J Invest Dermatol 113:1114-1118
Pulkkinen L, Uitto J (1998) Hemidesmosomal variants of epidermolysis bullosa: Mutations in 
the	α6β4 integrin and the 180-kD bullous pemphigoid antigen/type XVII collagen genes. Exp 
Dermatol 7:46-64
Pasmooij AMG, Pas HH, Deviaene FC, Nijenhuis M, Jonkman MF (2005) Multiple correcting 
COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am J Hum 
Genet 77:727-740
Whittock NV, Sher C, Gold I, Libman V, Reish O (2003) A founder COL17A1 splice site mutation 
leading to generalized atrophic benign epidermolysis bullosa in an extended inbred Palestinian 
family from Israel. Genet Med 5:435-439
McGrath JA, Darling T, Gatalica B, Pohla-Gubo G, Hintner H, Christiano AM, et al (1996) A 
homozygous deletion mutation in the gene encoding the 180-kDa bullous pemphigoid antigen 
(BPAG2) in a family with generalized atrophic benign epidermolysis bullosa. J Invest Dermatol 
106:771-774
van Leusden MR, Pas HH, Gedde-Dahl T, Sonnenberg A, Jonkman MF (2001) Truncated type 
XVII collagen expression in a patient with non-Herlitz junctional epidermolysis bullosa caused 
by a homozygous splice-site mutation. Lab Invest 81:887-894
Chapter 1
38
153. Franzke CW, Has C, Schulte C, Aumailley M, Balda BR, Bruckner-Tuderman L (2004) The la-
minin 5-binding domain of BP180/collagen XVII is important for structural integrity and adhesive 
functions. J Invest Dermatol 123:A15
	
